ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity

December 08, 2007

ATLANTA, GA, December 8, 2007 -- Results from two investigational Phase I trials of ZOLINZA® (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. Data from one study showed that 10 of 21 (48 percent) evaluable patients had a partial or minimal response from the ZOLINZA and bortezomib combination treatment. Data from a second study, sponsored by the United States National Cancer Institute under a Clinical Trials Agreement with Merck & Co., Inc., demonstrated 10 of 23 (43 percent) evaluable patients had a partial response or greater from the combination treatment. These data were presented today at the 49th Annual Meeting of the American Society of Hematology (Abstracts #1168 and #1172).

These trials are the first to evaluate the safety and efficacy of ZOLINZA as part of a combination regimen in patients with relapsed and/or refractory multiple myeloma. The primary objective of both trials was to determine the maximum tolerated dose (MTD) of ZOLINZA in combination with bortezomib in these patients. Bortezomib is regarded as a standard treatment option against multiple myeloma; the use of ZOLINZA in this patient population is investigational.

"With more than 50,000 men and women living with multiple myeloma, continued research is imperative, as patients eventually relapse after completing therapy," said Jose Garcia-Vargas, M.D., senior director, Clinical Oncology, Merck Research Laboratories. "These data provide a preliminary evaluation of the combination of vorinostat with bortezomib in patients with advanced multiple myeloma, including those who've previously received bortezomib therapy. Larger clinical studies are needed to confirm these results."

Study results

In the multicenter open-label, escalating-dose Phase I trial, a total of 24 patients with relapsed or refractory multiple myeloma were administered oral ZOLINZA 200 mg bid or 400 mg daily for 14 days in combination with bortezomib 0.7 or 0.9 mg/m2 I.V. on days 4, 8, 11 and 15 or in combination with bortezomib 0.9, 1.1, or 1.3 mg/m2 I.V. on days 1, 4, 8 and 11. Cycles were repeated every 21 days for a maximum of 8 cycles until progressive disease or intolerable toxicity. The primary objective was to determine MTD; secondary objectives included assessment of activity (using EBMT criteria) and safety and tolerability of the combination regimen. The median age of patients in the study was 61 years (45-76) and the median number of prior anti-cancer therapies was 3 (range of 1-14), with 25 percent (n=6) of patients previously treated with bortezomib.

Although the MTD has not yet been determined, of the 21 evaluable patients who received the combination regimen, as assessed using EBMT criteria, 48 percent had a partial (n=5) or minimal (n=5) response. Among the six patients previously treated with bortezomib, two achieved a partial response and three had a minimal response. Two patients experienced dose-limiting toxicities (transient AST elevation and thrombocytopenia). The most common drug-related adverse events among all patients were nausea (n=14), thrombocytopenia (n=13), diarrhea (n=12), vomiting (n=12), fatigue (n=10) anemia (n=6) and neutropenia (n=6). Accrual continues to determine the MTD.

In the second Phase I study lead by Dr. Ashraf Badros, University of Maryland, and sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute, 23 patients with relapsed or refractory multiple myeloma were administered oral ZOLINZA (100 mg bid, 200 mg bid, 400 mg daily or 500 mg daily) on days 4-11 over a 21-day period in combination with bortezomib (1.0 or 1.3 mg/m2 I.V. on days 1, 4, 8 and 11). Cycles were repeated every 21 days for a maximum of 8 cycles. If no response was observed at Cycle 2, dexamethasone 20 mg was added on days 4-8. The primary objective was to determine the MTD and pharmacokinetic and pharmacodynamic activity of the combination regimen. Patients also were evaluated for response and tolerability.

The median age of patients in the study was 54 years (39-78) and the median number of prior therapies was 7 (range of 3-13), with 19 patients previously treated with bortezomib.

Results of the study showed that the MTD for the combination regimen was achieved at ZOLINZA 400 mg daily for 8 days plus bortezomib 1.3 mg/ m2 days 1, 4, 8 and 11 respectively. Forty-three percent of patients had a partial response or greater (1 VGPR and 9 PR) following treatment with the ZOLINZA and bortezomib combination regimen, assessed using the International uniform response criteria for multiple myeloma. Among the 19 patients previously treated with bortezomib, one achieved a very good partial response and six had a partial response. Two patients experienced dose-limiting toxicities (fatigue and prolonged QT interval). Some of the non-hematological toxicities grade 2 and higher included fatigue (n=9), nausea (n=6), vomiting (n=3), diarrhea (n=3), pneumonia (n=3, bacterial and RSV), shingles (n=2) and atrial fibrillation (n=1).

"Based on these initial results presented for the first time, Merck is evaluating plans to accelerate testing of ZOLINZA in combination with bortezomib in the randomized clinical trial setting to further define the clinical activity in relapsed or refractory multiple myeloma," said Dr. Garcia-Vargas.
-end-
About ZOLINZA

ZOLINZA is the first histone deacetylase (HDAC) inhibitor approved by the U.S. Food & Drug Administration (FDA) for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

ZOLINZA works by inhibiting the enzymatic activity of HDAC1, HDAC2, HDAC3 (Class I) and HDAC 6 (Class II) at nanomolar concentrations (IC50 < 86nM). In some cancer cells, excess amounts of the enzyme HDAC prevent the activation of genes that control normal cell activity. Based on in vitro studies, ZOLINZA is believed to decrease the activity of HDAC, allowing for the activation of genes that may help to slow or stop the growth of cancer cells. The exact mechanism of the anticancer effect of ZOLINZA has not been fully characterized.

Important safety information about ZOLINZA

As pulmonary embolism and deep vein thrombosis have been reported as adverse reactions, physicians should be alert to the signs and symptoms of these events, particularly in patients with a prior history of thrombocytopenia. Treatment with ZOLINZA can cause dose-related thrombocytopenia and anemia. If platelet counts and/or hemoglobin are reduced during treatment with ZOLINZA, the dose should be modified or discontinued. Gastrointestinal disturbances, including nausea, vomiting and diarrhea, have been reported and may require the use of antiemetic and antidiarrheal medications. Fluid and electrolytes should be replaced to prevent dehydration. Pre-existing nausea, vomiting and diarrhea should be adequately controlled before beginning therapy with ZOLINZA.

Hyperglycemia has been observed in patients receiving ZOLINZA. Serum glucose should be monitored, especially in diabetic or potentially diabetic patients receiving ZOLINZA. Adjustment of diet and/or glucose therapy may be necessary. QTc prolongation has been observed. Monitor electrolytes and ECGs at baseline and periodically during treatment. Administer with caution in patients who have or may develop QTc prolongation. Hypokalemia or hypomagnesemia should be corrected prior to administration with ZOLINZA.

The most common adverse events observed in clinical trials with ZOLINZA for CTCL, regardless of causality, were fatigue (52 percent), diarrhea (52 percent), nausea (41 percent), dysgeusia (28 percent), thrombocytopenia (26 percent), anorexia (24 percent), decreased weight (21 percent) and muscle spasm (20 percent).

About Merck Oncology

Merck Oncology focuses on all aspects of cancer care - prevention, treatment, and supportive care. Through strong internal research capabilities, selective alliances and acquisitions, and enabling technologies such as the Molecular Profiling platform of Rosetta, Merck Oncology is looking to lead in the discovery, development and delivery of targeted anticancer therapies customized for patient subpopulations. Merck Oncology conducts research at sites in Boston, Seattle, West Point, Japan and Italy.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Cohn & Wolfe

Related Multiple Myeloma Articles from Brightsurf:

Penn Study supports use of radiation before CAR therapy for multiple myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.

New multiple myeloma therapy shows promise in preclinical study
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine.

A safer cell therapy harnesses patient T cells to fight multiple myeloma
A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease.

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response.

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.

Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.

BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.

Read More: Multiple Myeloma News and Multiple Myeloma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.